Clinical Trial Update: Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing capecitabine plus pyrotinib to capecitabine plus trastuzumab and pertuzumab for first-line treatment of HER2-positive metastatic breas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Pertuzumab (pertuzumab)
• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN